Your browser is no longer supported. Please, upgrade your browser.
AADI [NASD]
Aadi Bioscience, Inc.
Index- P/E- EPS (ttm)-11.63 Insider Own0.10% Shs Outstand20.89M Perf Week-11.54%
Market Cap419.99M Forward P/E- EPS next Y-3.23 Insider Trans0.00% Shs Float12.38M Perf Month-24.99%
Income-98.80M PEG- EPS next Q-0.98 Inst Own53.00% Short Float5.11% Perf Quarter-28.40%
Sales0.10M P/S4199.87 EPS this Y82.30% Inst Trans-2.50% Short Ratio3.07 Perf Half Y-37.55%
Book/sh15.87 P/B1.22 EPS next Y52.60% ROA-134.90% Target Price48.75 Perf Year-0.56%
Cash/sh7.45 P/C2.60 EPS next 5Y- ROE-147.00% 52W Range14.31 - 49.80 Perf YTD-19.71%
Dividend- P/FCF- EPS past 5Y30.90% ROI-14.70% 52W High-61.06% Beta1.52
Dividend %- Quick Ratio14.00 Sales past 5Y- Gross Margin- 52W Low35.49% ATR1.68
Employees12 Current Ratio14.00 Sales Q/Q- Oper. Margin- RSI (14)37.43 Volatility9.46% 7.12%
OptionableYes Debt/Eq0.04 EPS Q/Q-705.00% Profit Margin- Rel Volume0.60 Prev Close18.47
ShortableYes LT Debt/Eq0.04 Earnings- Payout- Avg Volume205.92K Price19.39
Recom1.60 SMA20-14.72% SMA50-16.02% SMA200-25.58% Volume123,650 Change4.98%
Jan-11-22Initiated Jefferies Buy $45
Oct-01-21Initiated Cowen Outperform
Sep-14-21Initiated Ladenburg Thalmann Buy $51
Sep-08-21Initiated Piper Sandler Overweight $45
Jan-18-22 02:57PM  
Jan-04-22 04:30PM  
Dec-28-21 09:38AM  
Dec-23-21 12:38PM  
Dec-21-21 09:38AM  
Dec-16-21 09:38AM  
Dec-08-21 09:38AM  
Nov-27-21 06:01AM  
06:01AM  
Nov-23-21 04:22PM  
06:00AM  
Nov-15-21 08:00AM  
Nov-13-21 01:35PM  
Nov-10-21 07:00AM  
Nov-09-21 08:00AM  
Nov-01-21 04:05PM  
Oct-25-21 08:00AM  
Oct-22-21 08:00AM  
Oct-19-21 05:22PM  
Oct-06-21 08:00AM  
Sep-20-21 08:30AM  
Sep-13-21 08:00AM  
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, ABI-009 (FYARRO) is a form of sirolimus bound to albumin. Aadi is evaluating ABI-009 in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was founded in 2011 and is headquartered in Pacific Palisades, California.